Helius Medical Technologies, a leading player in the neurotechnology sector, will be presenting at the upcoming ThinkEquity Conference on October 30, 2024.
The conference, held at the Mandarin Oriental Hotel in New York City, brings together institutional investors, corporate clients, and industry professionals to explore innovative advancements and financial strategies.
Helius, traded on Nasdaq as HSDT, focuses on developing novel therapeutic neuromodulation approaches to address balance and gait deficits.
During the conference, Helius's management team will discuss their advancements in neurotechnology and the potential impact of their products on patients with neurologic diseases.
In addition to the presentation, Helius will also engage in one-on-one meetings with interested investors throughout the day to discuss their innovative solutions and business strategies.
The ThinkEquity Conference is known for connecting companies with investors and offers a diverse lineup of presentations and networking opportunities.
Past conferences have attracted over 700 attendees and facilitated more than 500 one-on-one meetings, highlighting its importance as a venue for fostering relationships between companies and potential investors.
Helius Medical Technologies is a pioneer in developing solutions for neurologic deficits, utilizing an orally applied technology platform to enhance the brain's ability to engage in physiologic compensatory mechanisms.
The company's flagship product, the Portable Neuromodulation Stimulator, offers a non-invasive option for patients seeking relief from their symptoms.
By participating in events like the ThinkEquity Conference, Helius aims to build relationships that can facilitate future growth and expansion.
The company's commitment to research and development, coupled with its strategic engagement with investors, suggests a promising outlook for its future endeavors in the neurotech space.
With the ThinkEquity Conference on the horizon, Helius Medical Technologies is poised to make a significant impression on the investment community, showcasing its innovative approaches and the potential for growth in the neurotechnology sector.